HK inno.N Corporation will be responsible for the manufacture and supply of Tegoprazan, while Dr. Reddy's will handle local clinical development, registration, marketing and sales
The capex for FY22 stood at Rs 145 crore and is expected to be in the range of Rs 250-350 crore for the entire FY23 which would be funded through a mix of internal accruals and debt
To lay a technological foundation for developing exosome-based medicines and cosmetic products for dermatitis treatment
Novel approach driven by GN Corp Japan with potentials in neurological illnesses
This RT-PCR diagnostic kit helps in diagnosis of AS by detecting HLAB27 gene
The USFDA approval in AS marks the fifth indication for Rinvoq in chronic immune-mediated diseases
CLNK is a biotechnology research and development company that utilizes umbilical cord blood as the raw material to develop innovative, allogeneic, off-the-shelf, cell based therapeutic products
By strengthening the company's fibrotic disease development pipeline, Bridge will enhance its strategic focus on the development of comprehensive treatment solutions for idiopathic pulmonary fibrosis (IPF)
Launch of novel stent technology with 10-year safety and efficacy data adds further momentum to the company's global growth journey
An RMAT confers eligibility for accelerated approval and priority review of biologics licensing applications (BLA)
Subscribe To Our Newsletter & Stay Updated
